FARALLON CAPITAL MANAGEMENT, L.L.C.
Institutional investor · Portfolio as of Q1 2025
Top Holdings146 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
STATE STREET SPDR S&P 500 ETF TRUST CL USD INC | 3.3M | $1.8B | 8.9% | — | — | — | Decreased — |
HESS CORP | 5.4M | $866.5M | 4.2% | — | — | 6 qtrssince 2023-Q4 | Decreased 0 |
MICROSOFT CORP | 2.3M | $858.1M | 4.1% | $300.17 | +25.52% | 26 qtrssince 2018-Q4 | Increased 77 |
EXELIXIS INC | 22.5M | $831.9M | 4.0% | $19.15 | +91.64% | 26 qtrssince 2018-Q4 | Decreased 0 |
CAPITAL ONE FINANCIAL CO | 4.8M | $815.9M | 3.9% | — | — | 5 qtrssince 2024-Q1 | Increased 65 |
UNITEDHEALTH GROUP INC | 1.5M | $784.5M | 3.8% | $468.92 | +7.86% | 9 qtrssince 2023-Q1 | Increased 60 |
NATERA INC | 4.5M | $643.1M | 3.1% | $68.82 | +109.14% | 16 qtrssince 2021-Q2 | Increased 59 |
IQVIA HOLDINGS INC | 3.4M | $601.5M | 2.9% | $171.49 | +3.44% | 26 qtrssince 2018-Q4 | Increased 59 |
LANTHEUS HOLDINGS INC | 6M | $587.9M | 2.8% | $84.86 | +13.31% | 9 qtrssince 2023-Q1 | Increased 61 |
ARAMARK | 16.2M | $560.7M | 2.7% | $28.28 | +19.90% | 18 qtrssince 2020-Q4 | Increased 72 |
WALT DISNEY CO/THE | 5.5M | $542.5M | 2.6% | $96.39 | +0.63% | 4 qtrssince 2024-Q2 | Increased 66 |
SALESFORCE.COM INC | 2M | $527.9M | 2.5% | $227.43 | +17.94% | 22 qtrssince 2019-Q4 | Increased 78 |
AUTODESK INC | 2M | $522.9M | 2.5% | $294.73 | -11.23% | 2 qtrssince 2024-Q4 | Increased 58 |
INTUIT INC | 840,258 | $515.9M | 2.5% | $470.13 | +26.54% | 10 qtrssince 2022-Q4 | Increased 60 |
THERMO FISHER SCIENTIFIC INC | 1M | $515.4M | 2.5% | $468.31 | +6.51% | 22 qtrssince 2019-Q4 | Decreased 0 |
REVOLUTION MEDICINES INC | 13.5M | $478.6M | 2.3% | $34.68 | +7.69% | 17 qtrssince 2021-Q1 | Increased 55 |
ISHARES BIOTECHNOLOGY ETF | 3.6M | $460.4M | 2.2% | — | — | — | Unchanged — |
TRANSUNION | 5.4M | $449.2M | 2.2% | $85.96 | -4.71% | 26 qtrssince 2018-Q4 | Increased 54 |
NEW YORK TIMES CO-A | 8.9M | $443M | 2.1% | $42.57 | +13.64% | 20 qtrssince 2020-Q2 | Increased 64 |
INTRA-CELLULAR THERAPIES INC | 3.1M | $403M | 1.9% | — | — | 1 qtr | New 71 |
FARALLON CAPITAL MANAGEMENT, L.L.C. manages $20.9B across 146 positions as of Q1 2025. Top holdings: SPY (8.9%), HES (4.2%), MSFT (4.1%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 1.5/5.0.
Active quarter - 18 new positions, 20 exits, 43 increased. Top move: CRM (INCREASED, conviction 78). Portfolio: $20.9B across 146 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer